McLean Asset Management Corp Has $674,000 Position in Astrazeneca Plc $AZN

McLean Asset Management Corp lowered its holdings in Astrazeneca Plc (NYSE:AZN) by 47.4% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,418 shares of the company’s stock after selling 3,076 shares during the quarter. McLean Asset Management Corp’s holdings in Astrazeneca were worth $674,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in AZN. MV Capital Management Inc. acquired a new stake in Astrazeneca during the fourth quarter valued at approximately $26,000. Reflection Asset Management acquired a new position in shares of Astrazeneca in the 4th quarter worth approximately $31,000. Lloyd Advisory Services LLC. bought a new position in shares of Astrazeneca during the 4th quarter worth approximately $35,000. Basepoint Wealth LLC bought a new position in shares of Astrazeneca during the 4th quarter worth approximately $44,000. Finally, Acumen Wealth Advisors LLC acquired a new stake in Astrazeneca in the 4th quarter valued at $47,000. Institutional investors own 20.35% of the company’s stock.

Astrazeneca Price Performance

Shares of AZN stock opened at $188.58 on Monday. Astrazeneca Plc has a 52 week low of $137.23 and a 52 week high of $212.71. The stock has a market capitalization of $292.47 billion, a PE ratio of 28.32, a PEG ratio of 1.64 and a beta of 0.25. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.71 and a current ratio of 0.91. The stock’s fifty day moving average is $184.66 and its 200-day moving average is $187.16.

Astrazeneca (NYSE:AZN) last released its quarterly earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.52 by $0.06. The business had revenue of $15.29 billion during the quarter, compared to analysts’ expectations of $14.93 billion. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%. Equities research analysts expect that Astrazeneca Plc will post 9.39 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have issued reports on the company. Morgan Stanley reiterated an “overweight” rating on shares of Astrazeneca in a research note on Wednesday, April 8th. UBS Group restated a “buy” rating on shares of Astrazeneca in a research note on Friday, April 10th. Barclays reaffirmed a “buy” rating on shares of Astrazeneca in a report on Monday, June 1st. JPMorgan Chase & Co. reissued a “buy” rating on shares of Astrazeneca in a report on Tuesday, June 9th. Finally, Weiss Ratings cut shares of Astrazeneca from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday, June 18th. Twelve research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $205.33.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.